Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSPC PHARMA

6.050
+0.4908.81%
Volume:219.56M
Turnover:1.31B
Market Cap:69.84B
PE:15.46
High:6.150
Open:5.570
Low:5.570
Close:5.560
Loading ...

CSPC Pharmaceutical - FY Revenue for CSPC Innovation Pharmaceutical RMB1.98 Bln

THOMSON REUTERS
·
20 Mar

Greater China Stocks Close Mixed; Taiwan Leads Gainers

Dow Jones
·
20 Mar

3 Asian Penny Stocks With Market Caps Below US$8B

Simply Wall St.
·
19 Mar

BRIEF-Cspc Pharmaceutical Says JSKN003 Granted Breakthrough Therapy Designation

Reuters
·
18 Mar

CSPC Pharmaceutical's Anti-Tumor Drug Gets US FDA Nod for Clinical Trials

MT Newswires Live
·
14 Mar

BRIEF-CSPC Pharmaceutical Says SYH2051(Selective ATM Inhibitor) Obtains Clinical Trial Approval In U.S.

Reuters
·
13 Mar

CSPC Pharmaceutical - Syh2051 (Selective Atm Inhibitor) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
13 Mar

An Intrinsic Calculation For CSPC Pharmaceutical Group Limited (HKG:1093) Suggests It's 47% Undervalued

Simply Wall St.
·
08 Mar

CSPC Pharmaceutical Gets China Nod for Tumor Drug Clinical Trial

MT Newswires Live
·
06 Mar

BRIEF-CSPC Pharmaceutical Says JMT108 Obtains Clinical Trial Approval In China

Reuters
·
05 Mar

CSPC Pharmaceutical - Approval From National Medical Products Administration of China

THOMSON REUTERS
·
05 Mar

CSPC Pharmaceutical - Jmt108 (Bi-Functional Fusion Protein Drug) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
05 Mar

CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Anti-Tumor Indication of Sirolimus in China

MT Newswires Live
·
04 Mar

CSPC Pharmaceutical - Sirolimus for Injection (Albumin-Bound) Was Granted Breakthrough Therapy Designation in China

THOMSON REUTERS
·
28 Feb

Greater China Stocks Rise; Hong Kong Sees Largest Increase

Dow Jones
·
26 Feb

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.48 From HK$7.02, Keeps at Buy

MT Newswires Live
·
26 Feb

CSPC Pharmaceutical's 2024 Profit to Fall 26%; Shares Slide 4%

MT Newswires Live
·
26 Feb

BRIEF-CSPC Pharmaceutical Expects Decrease In Profit Attributable For Year Of 26%

Reuters
·
25 Feb

CSPC Pharmaceutical Sees Decrease in Profit Attributable for Year of 26%

THOMSON REUTERS
·
25 Feb

CSPC Pharmaceutical - Expected Result Due to Decrease in Revenue of Finished Drugs Business for Year

THOMSON REUTERS
·
25 Feb